Federal grants to Vaxnewmo
Vaxnewmo in Saint Louis, Missouri received $9.2 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Allergy and Infectious Diseases Research, with $9.2 million. In fiscal 2025 it was awarded $3.0 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$9.2 million
- Awards5
- Awarded in FY 2025$3.0 million
- Largest award$3.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $992,959 |
| FY 2022 | 3 | $1.6 million |
| FY 2023 | 3 | $1.6 million |
| FY 2024 | 2 | $2.0 million |
| FY 2025 | 3 | $3.0 million |
Programs that fund Vaxnewmo
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 5 | $9.2 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $9.2 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Development of a group b streptococcus bioconjugate vaccine - project summary streptococcus agalactiae, commonly referred to as group b streptococcus (GBS), is a leading cause of neonatal meningitis and sepsis worldwide. Gbs neonatal disease manifests as early onset invasive disease, defined as dise | Allergy and Infectious Diseases Research | June 14, 2023 | $3.0 million |
| A multivalent o-antigen bioconjugate vaccine for the prevention of klebsiella pneumoniae infections - project summary klebsiella pneumoniae is a leading cause of healthcare- and community-associated infections. Moreover, k. Pneumoniae is frequently resistant to last line antibiotics like third gener | Allergy and Infectious Diseases Research | July 6, 2022 | $2.6 million |
| Towards a new generation of glycoengineered pneumococcal bioconjugate vaccines | Allergy and Infectious Diseases Research | January 28, 2021 | $2.0 million |
| A capsule-based bioconjugate vaccine to prevent klebsiella pneumoniae infections - project summary klebsiella pneumoniae is a gram-negative, encapsulated human pathogen capable of causing community- acquired and healthcare-associated infections across all age groups. Further, k. Pneumoniae antimicro | Allergy and Infectious Diseases Research | August 25, 2025 | $1.0 million |
| A capsule-based bioconjugate vaccine to prevent klebsiella pneumoniae infections - project summary klebsiella pneumoniae is an encapsulated human pathogen capable of causing a myriad of human infections. Recently, k. Pneumoniae has also emerged as one the most common causes of secondary bacterial pn | Allergy and Infectious Diseases Research | December 27, 2021 | $593,112 |
Questions people ask
How much federal grant money does Vaxnewmo get?
$9.2 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Vaxnewmo the most?
The Department of Health and Human Services, with $9.2 million in 5 awards.
What is Vaxnewmo's largest federal grant?
$3.0 million under Allergy and Infectious Diseases Research, with its first action in the period on June 14, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Other grant recipients in Saint Louis
- The Washington University
- The Bi State Development Agency of the Mo IL Metro Dist
- City of St. Louis
- The City of St Louis
- Icl Specialty Products Inc
- Saint Louis University
- St. Louis County, Missouri
- St. Louis Housing Authority
Largest federal grant recipients in Missouri · Federal grants in Missouri